Evaluation of exhaled breath condensate pH as a biomarker for COPD

William MacNee, Stephen I. Rennard, John F. Hunt, Lisa D. Edwards, Bruce E. Miller, Nicholas W. Locantore, Ruth Tal-Singer

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Introduction: We assessed the utility of EBC pH as a biomarker in COPD in a large cohort of well-characterised individuals with COPD and control subjects from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. We also determined short term reproducibility and the response of EBC to oral prednisolone. Methods: EBC was collected with R-TubesTM, using techniques for sampling and measurement that have been shown to be reproducible. Results: EBC pH was lower in COPD (n = 676, 7.29 ± SD 0.60) and in smoking controls (n = 31, 7.18 ± 0.85), compared with non-smoking controls (n = 50, 7.59 ± 0.44, p = 0.0008 and 0.0033 respectively), but was not different between COPD and smoking controls. There was no relationship between EBC pH and disease severity, as assessed by the percent predicted FEV1, nor with airway inflammation as assessed by sputum leukocyte counts. Treatment with 20 mg.day-1 prednisolone for 4 weeks did not change EBC pH. Conclusion: EBC pH is lower in COPD than in healthy control non-smokers, but does not differentiate COPD from smokers without COPD, relate to disease severity or to airway inflammation, and does not respond to corticosteroids. EBC pH therefore does not appear to be a useful biomarker in COPD.

Original languageEnglish (US)
Pages (from-to)1037-1045
Number of pages9
JournalRespiratory Medicine
Volume105
Issue number7
DOIs
StatePublished - Jul 1 2011

Fingerprint

Chronic Obstructive Pulmonary Disease
Biomarkers
Prednisolone
Smoking
Inflammation
Sputum
Leukocyte Count
Adrenal Cortex Hormones

Keywords

  • Biomarkers
  • COPD
  • Exhaled breath condensate

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

MacNee, W., Rennard, S. I., Hunt, J. F., Edwards, L. D., Miller, B. E., Locantore, N. W., & Tal-Singer, R. (2011). Evaluation of exhaled breath condensate pH as a biomarker for COPD. Respiratory Medicine, 105(7), 1037-1045. https://doi.org/10.1016/j.rmed.2011.02.009

Evaluation of exhaled breath condensate pH as a biomarker for COPD. / MacNee, William; Rennard, Stephen I.; Hunt, John F.; Edwards, Lisa D.; Miller, Bruce E.; Locantore, Nicholas W.; Tal-Singer, Ruth.

In: Respiratory Medicine, Vol. 105, No. 7, 01.07.2011, p. 1037-1045.

Research output: Contribution to journalArticle

MacNee, W, Rennard, SI, Hunt, JF, Edwards, LD, Miller, BE, Locantore, NW & Tal-Singer, R 2011, 'Evaluation of exhaled breath condensate pH as a biomarker for COPD', Respiratory Medicine, vol. 105, no. 7, pp. 1037-1045. https://doi.org/10.1016/j.rmed.2011.02.009
MacNee W, Rennard SI, Hunt JF, Edwards LD, Miller BE, Locantore NW et al. Evaluation of exhaled breath condensate pH as a biomarker for COPD. Respiratory Medicine. 2011 Jul 1;105(7):1037-1045. https://doi.org/10.1016/j.rmed.2011.02.009
MacNee, William ; Rennard, Stephen I. ; Hunt, John F. ; Edwards, Lisa D. ; Miller, Bruce E. ; Locantore, Nicholas W. ; Tal-Singer, Ruth. / Evaluation of exhaled breath condensate pH as a biomarker for COPD. In: Respiratory Medicine. 2011 ; Vol. 105, No. 7. pp. 1037-1045.
@article{ece19d2cf0bd4b709765f64fc10a7f2f,
title = "Evaluation of exhaled breath condensate pH as a biomarker for COPD",
abstract = "Introduction: We assessed the utility of EBC pH as a biomarker in COPD in a large cohort of well-characterised individuals with COPD and control subjects from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. We also determined short term reproducibility and the response of EBC to oral prednisolone. Methods: EBC was collected with R-TubesTM, using techniques for sampling and measurement that have been shown to be reproducible. Results: EBC pH was lower in COPD (n = 676, 7.29 ± SD 0.60) and in smoking controls (n = 31, 7.18 ± 0.85), compared with non-smoking controls (n = 50, 7.59 ± 0.44, p = 0.0008 and 0.0033 respectively), but was not different between COPD and smoking controls. There was no relationship between EBC pH and disease severity, as assessed by the percent predicted FEV1, nor with airway inflammation as assessed by sputum leukocyte counts. Treatment with 20 mg.day-1 prednisolone for 4 weeks did not change EBC pH. Conclusion: EBC pH is lower in COPD than in healthy control non-smokers, but does not differentiate COPD from smokers without COPD, relate to disease severity or to airway inflammation, and does not respond to corticosteroids. EBC pH therefore does not appear to be a useful biomarker in COPD.",
keywords = "Biomarkers, COPD, Exhaled breath condensate",
author = "William MacNee and Rennard, {Stephen I.} and Hunt, {John F.} and Edwards, {Lisa D.} and Miller, {Bruce E.} and Locantore, {Nicholas W.} and Ruth Tal-Singer",
year = "2011",
month = "7",
day = "1",
doi = "10.1016/j.rmed.2011.02.009",
language = "English (US)",
volume = "105",
pages = "1037--1045",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Evaluation of exhaled breath condensate pH as a biomarker for COPD

AU - MacNee, William

AU - Rennard, Stephen I.

AU - Hunt, John F.

AU - Edwards, Lisa D.

AU - Miller, Bruce E.

AU - Locantore, Nicholas W.

AU - Tal-Singer, Ruth

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Introduction: We assessed the utility of EBC pH as a biomarker in COPD in a large cohort of well-characterised individuals with COPD and control subjects from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. We also determined short term reproducibility and the response of EBC to oral prednisolone. Methods: EBC was collected with R-TubesTM, using techniques for sampling and measurement that have been shown to be reproducible. Results: EBC pH was lower in COPD (n = 676, 7.29 ± SD 0.60) and in smoking controls (n = 31, 7.18 ± 0.85), compared with non-smoking controls (n = 50, 7.59 ± 0.44, p = 0.0008 and 0.0033 respectively), but was not different between COPD and smoking controls. There was no relationship between EBC pH and disease severity, as assessed by the percent predicted FEV1, nor with airway inflammation as assessed by sputum leukocyte counts. Treatment with 20 mg.day-1 prednisolone for 4 weeks did not change EBC pH. Conclusion: EBC pH is lower in COPD than in healthy control non-smokers, but does not differentiate COPD from smokers without COPD, relate to disease severity or to airway inflammation, and does not respond to corticosteroids. EBC pH therefore does not appear to be a useful biomarker in COPD.

AB - Introduction: We assessed the utility of EBC pH as a biomarker in COPD in a large cohort of well-characterised individuals with COPD and control subjects from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. We also determined short term reproducibility and the response of EBC to oral prednisolone. Methods: EBC was collected with R-TubesTM, using techniques for sampling and measurement that have been shown to be reproducible. Results: EBC pH was lower in COPD (n = 676, 7.29 ± SD 0.60) and in smoking controls (n = 31, 7.18 ± 0.85), compared with non-smoking controls (n = 50, 7.59 ± 0.44, p = 0.0008 and 0.0033 respectively), but was not different between COPD and smoking controls. There was no relationship between EBC pH and disease severity, as assessed by the percent predicted FEV1, nor with airway inflammation as assessed by sputum leukocyte counts. Treatment with 20 mg.day-1 prednisolone for 4 weeks did not change EBC pH. Conclusion: EBC pH is lower in COPD than in healthy control non-smokers, but does not differentiate COPD from smokers without COPD, relate to disease severity or to airway inflammation, and does not respond to corticosteroids. EBC pH therefore does not appear to be a useful biomarker in COPD.

KW - Biomarkers

KW - COPD

KW - Exhaled breath condensate

UR - http://www.scopus.com/inward/record.url?scp=79957521375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957521375&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2011.02.009

DO - 10.1016/j.rmed.2011.02.009

M3 - Article

C2 - 21377342

AN - SCOPUS:79957521375

VL - 105

SP - 1037

EP - 1045

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 7

ER -